Martijn van de Bunt

Company: Cytoki Pharma

Job title: Chief Scientific Officer

Seminars:

Looking Beyond Incretins with an Innovative IL-22 Therapy: A Novel Approach to Achieving Quality Weight Loss Without Muscle Loss 11:30 am

Explore how CK-0045, a first-in-class IL-22 analogue being investigated in a Phase 2a study, offers a unique approach to obesity treatment through a novel non-incretin-based mode-of-action in the gut which preserves muscle mass during weight loss Understand the potential of CK-0045 to be used as a standalone therapy or in combination with current standard treatments,…Read more

day: Conference Day One